Targeted drugs plus chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with esophageal squamous cell carcinoma (a common type of esophageal cancer) that has not spread to other organs.
- You have not had any previous treatment for your esophageal cancer, like surgery, chemotherapy, or radiation.
- You are generally healthy enough to undergo surgery and have good organ function (heart, lungs, liver, kidneys, and blood counts).
- You are not pregnant or breastfeeding, and you agree to use contraception during the study and for 6 months after.
- You do not have an active autoimmune disease, uncontrolled infection, or other serious medical condition that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.